Compare Motorola Solutions Inc (MSI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Sanofi SA — how do they compare? Motorola Solutions Inc trades at $446.54 (market cap $74.00B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Sanofi SA for 94 Days on average.
| MSI | SNY | |
|---|---|---|
Market Cap | $74.00B | $95.18B |
Volume | 722,147 | 2,995,646 |
Sector | Technology | Health |
52-Week High | $491.24 | $52.34 |
52-Week Low | $363.83 | $39.51 |
Typical Hold Time | 100 Days | 94 Days |
Enterprise Value | $82.90B | $114.48B |
Dividend Yield | 1.08% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and a record $15.6B backlog. Recent acquisitions like D-Fend Solutions and a $139M Louisiana public safety contract highlight expansion in security and AI-driven solutions. Earnings have consistently beaten estimates, with Q2 2026 EPS of $4.41 surpassing the $3.85 expectation. However, cash flow trends show significant investing outflows for growth initiatives.
The outlook remains positive given analyst consensus with a $525.86 price target and 70.59% buy ratings, though risks include high valuation multiples and increased debt levels from acquisitions. The stock's current bearish technical stance may present a buying opportunity if fundamentals continue to strengthen, but investors should monitor cash flow sustainability and integration of recent purchases.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
